Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)
Running, not enrolling · Phase 3
Conditions studied: Attention-Deficit/Hyperactivity Disorder
In brief
Open label extension, long-term multicenter study of safety and efficacy of SPN-812 in pediatric ADHD patients
Key facts
- Study ID
- NCT02736656
- Run by
- Supernus Pharmaceuticals, Inc.
- People needed
- 1400
- Starts
- 2016-02-02
- Expected to finish
- 2026-09-01
- Last updated by the study team
- 2026-07-15
Who can join
Age: 4 and older, up to 18. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Woodland International Research Group — Little Rock, Arkansas, United States
- Alliance for Wellness dba Alliance for Research — Long Beach, California, United States
- MCB Clinical Research Centers, LLC — Colorado Springs, Colorado, United States
- Meridien Research at Florida Clinical Research Center — Bradenton, Florida, United States
- Sarkis Clinical Trials — Gainesville, Florida, United States
- Indago Research & Health Center, Inc. — Hialeah, Florida, United States
- Florida Clinical Research Center, LLC. — Maitland, Florida, United States
- Florida Clinical Research Center, LLC — Maitland, Florida, United States
- IPS Research — Oklahoma City, Oklahoma, United States
- Paradigm Research Professionals — Oklahoma City, Oklahoma, United States
- Clinical Neuroscience Solutions, Inc. — Memphis, Tennessee, United States
- CNS Healthcare — Memphis, Tennessee, United States
- Bayou City Research Corporation — Houston, Texas, United States
- Road Runner Research — San Antonio, Texas, United States
- Ericksen Research & Development — Clinton, Utah, United States
- Northwest Clinical Trials — Bellevue, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.